Oct 11, 2024 06:37AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Oct 8, 2024 06:49AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Sep 6, 2024 06:55AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Aug 12, 2024 06:13AM Akebia Therapeutics (AKBA) PT Raised to $7.50 at H.C. Wainwright

Apr 1, 2024 11:09AM Akebia Therapeutics (AKBA) PT Raised to $6 at H.C. Wainwright, 'favorable label to daprodustat'

Aug 28, 2023 06:08AM H.C. Wainwright Upgrades Akebia Therapeutics (AKBA) to Buy, 'What we have been waiting for'

Jul 1, 2022 06:07AM H.C. Wainwright Reiterates Buy Rating, $1.25 Price Target on Akebia Therapeutics (AKBA)

Apr 8, 2022 06:11AM H.C. Wainwright Reiterates Neutral Rating, $2 PT on Akebia Therapeutics (AKBA)

Mar 31, 2022 07:11AM UPDATE: H.C. Wainwright Downgrades Akebia Therapeutics (AKBA) to Neutral

Feb 23, 2022 10:35AM H.C. Wainwright Reiterates Buy Rating on Akebia Therapeutics (AKBA)

Aug 6, 2019 07:14AM Akebia Therapeutics (AKBA) PT Lowered to $17 at H.C. Wainwright

Jul 11, 2019 07:16AM Akebia Therapeutics (AKBA) PT Lowered to $21 at H.C. Wainwright

Apr 3, 2019 08:45AM Akebia Therapeutics (AKBA) PT Raised to $23 at H.C. Wainwright

Jul 10, 2017 07:49AM Akebia Therapeutics (AKBA): Cutting PT By $1 On Capital Raise Dilution - HC Wainwright

Jun 6, 2017 07:56AM Akebia Therapeutics (AKBA): Another Patent Win - HC Wainwright

May 16, 2017 07:26AM Akebia Therapeutics (AKBA): Raising PT On Key Contract - HC Wainwright

Apr 27, 2017 07:43AM Akebia Therapeutics (AKBA): European Partnership Removes Funding Concerns - HC Wainwright

Dec 27, 2016 07:30AM Akebia Therapeutics (AKBA): Phase III Funding In The Bag - HC Wainwright; PT up to $18